Clinical Network Services is Australia's favourite CRO
Clinical Network Services (CNS), an integrated service group focused on clinical product development, has been announced as Australia’s favourite CRO for 2015 by ARCS Australia, a professional development association for people working in the development of therapeutic goods.
The award was based on votes from international and local sponsors as well as local investigational sites. It was presented by ARCS CEO Adrian Bootes during the 2015 ARCS Scientific Congress, held in Sydney from 5-7 May.
“ARCS would like to help recognise the efforts of those working in the development of therapeutics by awarding companies and sites, as nominated by their peers,” said Bootes. “Being chosen as the favourite CRO wasn’t simply a reflection of CNS’s systems and processes, but was also an acknowledgment of the people, who are the essential glue.”
“CNS is proud and honoured to have won this award,” said CNS Chief Operating Officer Gabrielle McKee. “As a company, CNS has always been committed to maintaining a positive culture focused on how we interact with each other, our clients and, importantly, the wonderful clinicians, coordinators and pharmacists who are at the forefront of delivering our trials to patients.”
“We have never been a group motivated by the limelight or winning awards,” added CNS Managing Director Russell Neal, “but recognition from those we work with every day is a wonderful validation of the emphasis CNS places in our working relationships, whether that be with our site colleagues, our clients and indeed with each other. It’s the personal touch that continues to underpin CNS’s growth and success.”
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
